Is the duration of dual antiplatelet therapy (DAPT) excessive in post-angioplasty in chronic coronary syndrome? Data from the France-PCI registry (2014–2019)

Is the duration of dual antiplatelet therapy (DAPT) excessive in post-angioplasty in chronic coronary syndrome? Data from the France-PCI registry (2014–2019)

Backgroundwhile the duration of dual antiplatelet therapy (DAPT) following coronary angioplasty for chronic coronary syndrome (CCS) recommended by the European Society of Cardiology has decreased over the last decade, little is known about the adherence to those guidelines in clinical practice in Fr...

Full description

Bibliographic Details
Main Authors: A. Mezier, P. Motreff, J. M. Clerc, O. Bar, R. Deballon, T. Demicheli, T. Dechery, G. Souteyrand, A. Py, N. Lhoest, T. Lhermusier, B. Honton, A. Gommeaux, J. Jeanneteau, P. Deharo, H. Benamer, G. Cayla, R. Koning, B. Pereira, J. P. Collet, G. Rangé
Format: Article
Language:English
Published: Frontiers Media S.A. 2023-03-01
Series:Frontiers in Cardiovascular Medicine
Subjects:
coronary angioplasty
chronic coronary syndrome
dual antiplatelet therapy
bleeding risk
ischemic risk
Online Access:https://www.frontiersin.org/articles/10.3389/fcvm.2023.1106503/full

Similar Items

Similar Items